Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MBX Biosciences, Inc. (MBX)
NASDAQ:MBX
MBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.63 - $27.50
Previous CloseN/A
Volume52.29K
Average Volume (3M)309.35K
Market Cap
$395.33M
Enterprise Value$590.33M
Total Cash (Recent Filing)42.46M
Total Debt (Recent Filing)324.00K
Price to Earnings (P/E)―
Beta0.94
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,417,420
10 Day Avg. Volume312,371
30 Day Avg. Volume309,351
Standard Deviation0.17
R-Squared0.08
Alpha-0.18
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$40.00Price Target Upside267.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
MBX Biosciences, Inc. News
PremiumCompany Announcements
MBX Biosciences Reports Q3 2024 Financial Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPhase I results for MBX 1416 support the potential for once-weekly dosing with a significant signal on GLP-1 concentrations.
Market PotentialThe lead Phase II program has $2.5B+ peak sales potential and shown positive Phase I PK data with dose proportional increase in mean concentration and a 7-9 day half-life supporting weekly dosing.
Bears Say
Adverse ReactionsInstances of Grade 3 injection site reactions were observed, though 88% were mild or moderate and resolved within about 7 days.
---
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $8.63 and its highest was $27.50 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $395.33M.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on Nov 07, 2024. The company reported -$2.78 earnings per share for the quarter, missing the consensus estimate of -$2.717 by -$0.063.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 33,417,420 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$2.78 in its last earnings report, missing expectations of -$2.717. Following the earnings report the stock price went up 2.066%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
---
MBX Biosciences, Inc. Stock Smart Score
Company Description
MBX Biosciences, Inc.
MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders. Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. We designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration.
---
MBX Stock 12 Month Forecast
Average Price Target
$40.00
▲(267.65% Upside)
Technical Analysis
Best Analysts Covering MBX
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
-22.10%
reiterated a buy rating 13 days ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -22.10% per trade.
---